Building an EU Action Plan to drive forward the elimination of viral Hepatitis by 2030

The HCV national strategy in Spain

Dra. Julia del Amo
Director of Control Plans for HIV & STIs & Viral Hepatitis & TB
General Directorate of Public Health, Quality and Innovation
Ministry of Health, Consumers Affaires and Social Welfare
Outline

• Strategic Plan to Address Hepatitis C in the National Health System

• Epidemiology of HCV infection in Spain:
  – Prevalence in general population; 2017-2018
  – Prevalence in high-risk settings; 2012-2018

• Public health & policy on HCV screening in Spain
Outline

• Strategic Plan to Address Hepatitis C in the National Health System

• Epidemiology of HCV infection in Spain:
  – Prevalence in general population; 2017-2018
  – Prevalence in high-risk settings; 2012-2018

• Public health & policy on HCV screening in Spain
Strategic Plan to Address Hepatitis C in the National Health System (PEAHC)
Objective of PEACH

To reduce morbidity and mortality rates in the Spanish population, addressing the prevention, diagnosis, treatment and monitoring of people infected with HCV.
Strategic Plan to Address Hepatitis C in the National Health System
Patients treated with DAAs

By 1\textsuperscript{st} October 2019: 134,676 patients on DAAs
Stages of Fibrosis at time of DAA initiation: 2015-2019

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>F4</td>
<td>50.22%</td>
<td>27.76%</td>
<td>11.43%</td>
<td>13.88%</td>
</tr>
<tr>
<td>F3</td>
<td>20.26%</td>
<td>18.04%</td>
<td>8.56%</td>
<td>8.82%</td>
</tr>
<tr>
<td>F2</td>
<td>21.33%</td>
<td>33.18%</td>
<td>16.74%</td>
<td>13.28%</td>
</tr>
<tr>
<td>F1</td>
<td>6.99%</td>
<td>19.69%</td>
<td>62.04%</td>
<td>58.28%</td>
</tr>
<tr>
<td>F0</td>
<td>0.71%</td>
<td>0.69%</td>
<td>0.36%</td>
<td>4.16%</td>
</tr>
<tr>
<td>Sin datos</td>
<td>0.49%</td>
<td>0.64%</td>
<td>0.87%</td>
<td>1.59%</td>
</tr>
</tbody>
</table>

Fuente de datos SITHepaC: 36.014 pacientes
Outline

• Strategic Plan to Address Hepatitis C in the National Health System

• Epidemiology of HCV infection in Spain:
  – Prevalence in general population; 2017-2018
  – Prevalence in high-risk settings; 2012-2018

• Public health & policy on HCV screening in Spain
• Decision making in public health needs to be supported by the best available epidemiological evidence

• First strategic line of the PEAC
  – Population based study to estimate the prevalence of HCV infection in the general population in Spain
Methodology

- **Study design:** Population-based survey
- **Setting:** persons aged 2 to 80 living in Spain
- **Sampling strategy:**

  For confirmed and undetermined HCV cases, letters were sent to health professional requesting further information regarding whether the case was previously known or not, as well as requesting information on HCV risk factors, linkage to care and treatment with DAAs.
**N= 7 675 participants**

**HCV Ab prevalence 0.85% (0.64%-1.08%)**

**HCV active infection 0.22% (0.13%-0.31%)**
# Prevalence of HCV Ab and active HCV infection

<table>
<thead>
<tr>
<th>Age group</th>
<th>Prevalence of Ab</th>
<th>Prevalence of active infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-80 years</td>
<td>0.69% (IC 95%: 0.50%-0.87%)</td>
<td>0.17% (IC 95%: 0.08%-0.28%)</td>
</tr>
<tr>
<td>2-19 years</td>
<td>0.00% (IC 95%: 0.00%-0.00%)</td>
<td>0.00% (IC 95%: 0.00%-0.00%)</td>
</tr>
<tr>
<td>20-80 years</td>
<td>0.85% (IC 95%: 0.64%-1.08%)</td>
<td>0.22% (IC 95%: 0.12%-0.32%)</td>
</tr>
</tbody>
</table>

Undiagnosed fraction 19%

Undiagnosed fraction 29%
HCV antibody prevalence by age and sex between 20 and 80 years
Active HCV infection prevalence by age and sex between 20 and 80 years

Men aged 50-59
0.86% (95%CI: 0.28-1.57)
Gráfico 6. Prevalencia de anticuerpos según clase social y sexo de 20 a 80 años.


<table>
<thead>
<tr>
<th>Clase Social</th>
<th>Hombre</th>
<th>Mujer</th>
<th>Hombre</th>
<th>Mujer</th>
<th>Hombre</th>
<th>Mujer</th>
</tr>
</thead>
<tbody>
<tr>
<td>I (Favorecida)</td>
<td>1,02%</td>
<td>0,52%</td>
<td>1,30%</td>
<td>0,66%</td>
<td>2,25%</td>
<td>0,91%</td>
</tr>
<tr>
<td>II (Media)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III (Desfavorecida)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IC 95% LS
- Hombre: 1,02% ± 0,19% (0,56%)
- Mujer: 0,52% ± 0,03% (0,23%)
- Hombre: 1,30% ± 0,17% (0,70%)
- Mujer: 0,66% ± 0,03% (0,34%)
- Hombre: 2,25% ± 1,35% (1,77%)
- Mujer: 0,91% ± 0,36% (0,63%)

IC 95% LI
- Hombre: 1,02% ± 0,19% (0,56%)
- Mujer: 0,52% ± 0,03% (0,23%)
- Hombre: 1,30% ± 0,17% (0,70%)
- Mujer: 0,66% ± 0,03% (0,34%)
- Hombre: 2,25% ± 1,35% (1,77%)
- Mujer: 0,91% ± 0,36% (0,63%)

Prevalencia
- Hombre: 1,02% ± 0,19% (0,56%)
- Mujer: 0,52% ± 0,03% (0,23%)
- Hombre: 1,30% ± 0,17% (0,70%)
- Mujer: 0,66% ± 0,03% (0,34%)
- Hombre: 2,25% ± 1,35% (1,77%)
- Mujer: 0,91% ± 0,36% (0,63%)

MINISTERIO DE SANIDAD, CONSUMO Y BIENESTAR SOCIAL
In population terms, in Spain, in 2018:

- 34 753 283 million inhabitants aged 20 - 80 years
- Given an HCV active infection prevalence 0.22%
  - 76 839 persons with active HCV infection
- Given an undiagnosed fraction of 29.4%
  - 22 478 persons with undiagnosed active HCV infection
  - 54 361 persons with diagnosed active HCV infection
    - 50% on DAA: 27 181
    - 17% with no evidence of linkage to care: 9 241
    - 33% with no information: 17 939
Outline

• Strategic Plan to Address Hepatitis C in the National Health System

• Epidemiology of HCV infection in Spain:
  – Prevalence in general population; 2017-2018
  – Prevalence in high-risk settings; 2012-2018

• Public health & policy on HCV screening in Spain
HCV prevalence in Prison Settings in Spain (except Catalonia and Basque Country)

<table>
<thead>
<tr>
<th>Year</th>
<th>anti-VHC</th>
<th>RNA VHC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>19.5%</td>
<td>11.0%</td>
</tr>
<tr>
<td>2016</td>
<td>18.7%</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>16.7%</td>
<td>9.0%</td>
</tr>
<tr>
<td>2018</td>
<td>10.5%</td>
<td>3.0%</td>
</tr>
<tr>
<td>2019 (*)</td>
<td>10.1%</td>
<td>1.9%</td>
</tr>
</tbody>
</table>

(*) Datos de junio de 2019, pendientes de publicación.
HCV prevalence in HIV-positive population in Spain (GeSIDA studies)

Fanciulli, C, et al. 17th European AIDS Conference. Abstract # PE37/10

6. Current study
Outline

• Strategic Plan to Address Hepatitis C in the National Health System

• Epidemiology of HCV infection in Spain:
  – Prevalence in general population; 2017-2018
  – Prevalence in high-risk settings; 2012-2018

• Public health & policy on HCV screening in Spain
Health governance and decision making in screening policies

National Committee of Public Health

Interterritorial Health Council
Once a population-based screening strategy is approved by the National Committee of Public Health and the Interterritorial Council, autonomous regions have 5 years to implement it and up to 10 to reach 100% coverage.
None of these plans recommend population-based screening for HCV infection
Technical group on HCV screening
Madrid, 16th of July 2019

Ministry of Health

PEAHC Scientific Advisory Board

Commission for public health screening

HCV surveillance

Directors of HCV Elimination Plans

Public Health Prison Department

Presidents of Primary Health Care scientific societies

Presidents of Hepatology and Infectious Diseases scientific societies

Follow-up TC on 22nd November: HCV Guidance in process
Thank you for your attention